The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay
- 340 Downloads
Recent studies focused on angiogenesis in the pathophysiology of bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) and identified geranylgeraniol (GGOH) as a feasible option for BP-ONJ therapy. This study investigated the influence of GGOH on microvessel sprouting after BP-incubation in vitro.
Materials and methods
Ten experimental set-ups were randomly designed in an in vitro 3D-angiogenesis assay. Two groups included HUVEC cell spheroids with and without (±) GGOH substitution as controls and eight groups pairwise contained either clodronate or the nitrogen-containing bisphosphonates (N-BP) ibandronate, pamidronate, and zoledronate ± GGOH. The size of the cell spheroids including the outbranching sprouts (SpS) as well as the density (SpD) and length of the sprouts (SpL) were analyzed by a grid system after 0, 24, 48, and 72 h.
For controls and NN-BP clodronate, no significant differences at any tested parameter and any point of measurement could be detected within the experimental set-ups ± GGOH (p each ≥0.05). For N-BP ibandronate, the experimental set-ups +GGOH showed a significantly increased SpS, SpD, and SpL after 48 and 72 h (p each ≤0.002) compared to the experimental set-ups −GGOH. For N-BPs pamidronate and zoledronate, the experimental set-ups + GGOH demonstrated a significantly increased SpS, SpD, and SpL after 24, 48, and 72 h (p each ≤0.001) compared to the experimental set-ups −GGOH.
The strong negative influence of N-BPs on microvessel sprouting could be significantly reversed by GGOH.
Since supportive therapeutic options for BP-ONJ are lacking, GGOH might be a promising substitute for BP-ONJ prevention and therapy.
KeywordsBisphosphonate BP-ONJ Osteonecrosis Isoprenoid Geranylgeraniol Angiogenesis
The authors give special thanks to Kathy Taylor for proof-reading and language checking.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
No fundings were received for this study. The work was supported by the Department of Oral and Maxillofacial Surgery, University Medical Center, Augustusplatz 2, 55131 Mainz, Germany.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study, formal consent is not required.
- 11.Ziebart T, Pabst A, Klein MO, Kaemmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105–111CrossRefPubMedGoogle Scholar
- 12.Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2014) Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D matrigel assay. Clin Oral Investig 18:1015–1022CrossRefPubMedGoogle Scholar
- 18.Assaf AT, Zrnc TA, Riecke B, Wikner J, Zustin J, Friedrich RE, Heiland M, Smeets R, Grobe A (2014) Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Oral Maxillofac Surg 42:157–164Google Scholar
- 21.Blus C, Szmukler-Moncler C, Giannelli G, Denotti G, Orru G (2013) Use of ultrasonic bone surgery (Piezosurgery) to surgically treat bisphosphonate-related osteonecrosis of the jaws (BRONJ). A case series report with at least 1 year follow-up. Open Dent J 7:94–101CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Favia G, Piattelli A, Sportelli P, Capodiferro S, Iezzi G (2011) Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res 13:58–63Google Scholar
- 40.Wehrhan F, Hyckel P, Ries J, Stockmann P, Nkenke E, Schlegel KA, Neukam FW, Amann K (2010) Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features. J Transl Med 8:96CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T, Neukam FW, Amann K (2011) Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:216–221CrossRefPubMedGoogle Scholar
- 48.Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S, Knowles A, Marcuzzi A (2014) Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 15:6843–6856CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Marcuzzi A, Decorti G, Pontillo A, Ventura A, Tommasini A (2010) Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. Inflamm Res 59:335–338CrossRefPubMedGoogle Scholar